Clinical observation of erythropoietin in treating the anemia induced by chemotherapy
- VernacularTitle:冲击剂量重组人促红细胞生成素治疗乳腺癌患者化疗所致贫血的临床研究
- Author:
Jian HUANG
;
Zhan-Hong CHENG
;
Wei-Wu YE
;
Xiao-Jia WANG
;
- Publication Type:Journal Article
- Keywords:
Breast neoplasms;
Anemia;
Erythropoietin,recombination;
Impact dose
- From:
Cancer Research and Clinic
1999;0(05):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective Observe the response and adverse effects of impact dose recombination human erythropoietin(rhEPO)in the breast cancer patients with anemia induced by chemotherapy.Methods 43 breast cancer patients with anemia induced by chemotherapy were randomly divided into two groups,treatment group(23 patients)and the control(20 patients).The treatment group received rhEPO for 10 days and oral iron therapy,while the control group was oral iron therapy only.Results After 4 weeks,the hemoglobin level, hematocrit,reticulocyte and quality of life be revaluated,the treatment group was significantly better than the control.The adverse effects was tolerable.Conclusion The impact dose rhEPO is effective and tolerable in the breast cancer patients with anemia induced by chemotherapy.
